Literature DB >> 18415107

[Tamoxifen retinopathy: a case series of clinical and functional data].

C Ritter1, A B Renner, J Wachtlin, N E Bechrakis, L Krause.   

Abstract

BACKGROUND: Tamoxifen is used in the treatment of selected patients with breast carcinoma. Rarely, it has been shown to cause ocular toxic effects including crystalline retinopathy.
METHODS: Retrospective analysis of clinical and functional (visual acuity, visual field, colour vision) data of a case series of eight female patients under tamoxifen therapy with electrophysiological examination.
RESULTS: Seven of eight patients complained of visual disturbances. In one case, examination showed crystalline deposits in the cornea and macular area. Three patients revealed changes in full-field and multifocal electroretinogram, and two had a pathological multifocal electroretinogram only. In six cases we applied a desaturated panel D-15 colour vision test; five of these showed some disorders.
CONCLUSIONS: Most tamoxifen patients who complained of visual disturbances showed electrophysiological changes, particularly in the multifocal electroretinogram and often without a certain morphological correlate. We recommend electrophysiological examination for patients with unclear visual deterioration who are receiving tamoxifen therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18415107     DOI: 10.1007/s00347-007-1677-8

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  29 in total

1.  Tamoxifen maculopathy.

Authors:  Amar Alwitry; Iain Gardner
Journal:  Arch Ophthalmol       Date:  2002-10

2.  Standard for clinical electroretinography (2004 update).

Authors:  Michael F Marmor; Graham E Holder; Mathias W Seeliger; Shuichi Yamamoto
Journal:  Doc Ophthalmol       Date:  2004-03       Impact factor: 2.379

3.  Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials.

Authors:  Lorenzo Gianni; Ilaria Panzini; Sigui Li; Richard D Gelber; John Collins; Stig B Holmberg; Diana Crivellari; Monica Castiglione-Gertsch; Aron Goldhirsch; Alan S Coates; Alberto Ravaioli
Journal:  Cancer       Date:  2006-02-01       Impact factor: 6.860

4.  [Electrophysiological studies in breast carcinoma patients with tamoxifen retinopathy].

Authors:  J Kuchenbecker; C Pump-Schmidt; S Olbricht; W Weise; W Behrens-Baumann
Journal:  Ophthalmologe       Date:  2001-01       Impact factor: 1.059

5.  Tamoxifen therapy conveys increased risk of developing a macular hole.

Authors:  Brendan G Cronin; Christopher K Lekich; Robert D Bourke
Journal:  Int Ophthalmol       Date:  2006-09-15       Impact factor: 2.031

6.  Optical coherence tomography findings in tamoxifen retinopathy.

Authors:  Vincent Gualino; Salomon Y Cohen; Marie-Noëlle Delyfer; José-Alain Sahel; Alain Gaudric
Journal:  Am J Ophthalmol       Date:  2005-10       Impact factor: 5.258

Review 7.  Tamoxifen-associated eye disease. A review.

Authors:  S G Nayfield; M B Gorin
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

8.  Tamoxifen retinopathy: does it really exist?

Authors:  F Lazzaroni; L Scorolli; C F Pizzoleo; G Savini; A De Nigris; F Giosa; R A Meduri
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1998-09       Impact factor: 3.117

9.  Screening for ocular toxicity in asymptomatic patients treated with tamoxifen.

Authors:  J S Heier; R A Dragoo; R W Enzenauer; W J Waterhouse
Journal:  Am J Ophthalmol       Date:  1994-06-15       Impact factor: 5.258

10.  Tamoxifen induces changes in the lipid composition of the retinal pigment epithelium cell line D407.

Authors:  Maria Engelke; Svitlana Tykhonova; Michaela Zorn-Kruppa; Horst Diehl
Journal:  Pharmacol Toxicol       Date:  2002-07
View more
  6 in total

1.  [Unusual symptoms for tamoxifen-associated maculopathy].

Authors:  T Hager; S Hoffmann; B Seitz
Journal:  Ophthalmologe       Date:  2010-08       Impact factor: 1.059

2.  Electrophysiological assessment for early detection of retinal dysfunction in β-thalassemia major patients.

Authors:  Maria Dettoraki; Antonis Kattamis; Ioannis Ladas; Konstantinos Maragkos; Chryssanthi Koutsandrea; Klio Chatzistefanou; Konstantinos Laios; Dimitrios Brouzas; Marilita M Moschos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-03-30       Impact factor: 3.117

3.  Retinal function in patients treated with tamoxifen.

Authors:  Sung Eun Song Watanabe; Adriana Berezovsky; Márcia Motono; Paula Yuri Sacai; Josenilson Martins Pereira; Juliana Maria Ferraz Sallum; Luiz Henrique Gebrim; Solange Rios Salomão
Journal:  Doc Ophthalmol       Date:  2010-04       Impact factor: 2.379

Review 4.  Breast cancer medications and vision: effects of treatments for early-stage disease.

Authors:  Alvin Eisner; Shiuh-Wen Luoh
Journal:  Curr Eye Res       Date:  2011-08-05       Impact factor: 2.424

Review 5.  Ocular side effects of biological agents in oncology: what should the clinician be aware of?

Authors:  Tobias Hager; B Seitz
Journal:  Onco Targets Ther       Date:  2013-12-24       Impact factor: 4.147

6.  Imaging tamoxifen retinopathy using spectral-domain optical coherence tomography.

Authors:  Albert Caramoy; Paula Scholz; Sascha Fauser; Bernd Kirchhof
Journal:  GMS Ophthalmol Cases       Date:  2011-12-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.